{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-007011","form_type":"8-K","ticker":"ACET","cik":"0001720580","company_name":"Adicet Bio, Inc.","filed_at":"2024-01-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.243400+00:00","generated_at":"2026-06-06T19:19:59.932245+00:00","sec_items":["1.01","2.02","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Adicet Bio prices $85.2M public offering of common stock and warrants at $2.40/share","bullets":["Offered 27,054,667 shares at $2.40 and 8,445,333 pre-funded warrants at $2.3999; gross proceeds ~$85.2M.","Net proceeds estimated ~$91.8M after underwriting discount and expenses; offering closes Jan 25.","Underwriters' option for additional 5,325,000 shares exercised in full on Jan 23.","As of Dec 31, 2023, preliminary cash and cash equivalents $159.7M.","ATM sales since Sep 30: 6.35M shares at avg $3.13 for net $19.3M."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-007011","json":"https://secwatch.observer/filing/0000950170-24-007011.json","markdown":"https://secwatch.observer/filing/0000950170-24-007011.md","text":"https://secwatch.observer/filing/0000950170-24-007011.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1720580/000095017024007011/0000950170-24-007011-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1720580/000095017024007011/acet-20240122.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T19:19:59.932245+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0a0483c0aaac734bf6465169934c4ceab756fbc3","claim":"Adicet Bio, Inc. entered into Underwriting Agreement with Jefferies LLC and Guggenheim Securities, LLC, as representatives of the several underwriters (effective 2024-01-22).","evidence_excerpt":"On January 22, 2024, Adicet Bio, Inc. (the “Company”) entered into an Underwriting Agreement (the “Underwriting Agreement”) with Jefferies LLC and Guggenheim Securities, LLC, as representatives of the several underwriters listed on Schedule A thereto (the “Underwriters”), related to an underwritten public offering (the “Offering”) of 27,054,667 shares (the “Shares”) of common stock of the Company, par value $0.0001 per share (the “Common Stock”), and, in lieu of Common Stock to an investor, pre-funded warrants (the “Pre-Funded Warrants”) to purchase 8,445,333 shares of Common Stock (the “Warrant Shares”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1720580/000095017024007011/0000950170-24-007011-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"underwriting"},{"label":"Counterparty","value":"Jefferies LLC and Guggenheim Securities, LLC, as representatives of the several underwriters"},{"label":"Effective","value":"2024-01-22"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}